Filed pursuant to Rule 433
Registration Statement No. 333-180300-03
FINANCIAL PRODUCTS
FACT SHEET (T299)
|
|
Offering Period: February 4, 2014 – February 20, 2014
6 Year Accelerated Barrier Notes Linked to the EURO STOXX 50
®
Index
Product Summary
|
•
|
|
6 year Accelerated Barrier Notes linked to the performance of the EURO STOXX 50
®
Index.
|
|
•
|
|
If the Final Level is equal to or greater than the Initial Level, you will be entitled
to receive leveraged participation in the appreciation of the Underlying.
|
|
•
|
|
If the Final Level is less than the Initial Level and a Knock-In Event does not occur,
you will be entitled to receive the principal amount at maturity.
|
|
•
|
|
If the Final Level is less than the Initial Level and a Knock-In Event occurs, you
will be fully exposed to any depreciation in the Underlying.
|
|
•
|
|
Any payment on the securities is subject to our ability to pay our obligations as
they become due.
|
|
•
|
|
Credit Suisse currently estimates that the value of the securities on the Trade Date
will be less than the price you pay for the securities, reflecting the deduction of underwriting discounts and commissions and
other costs of creating and marketing the securities.
|
Terms
|
Issuer:
|
Credit Suisse AG (“Credit Suisse”), acting through one of its branches
|
|
Trade Date:
|
Expected to be February 21, 2014
|
|
Settlement Date:
|
Expected to be February 28, 2014
|
|
Underlying:
|
The EURO STOXX 50
®
Index
|
|
Upside Participation Rate*:
|
Expected to be between 150% and 160%.
|
|
Redemption Amount:
|
Principal Amount * (1 + Underlying Return).
|
|
Underlying Return:
|
If (a) the Final Level is equal to or greater than the Initial Level, then [(Final Level – Initial Level)/Initial Level] * Upside Participation Rate, or (b) the Final Level is less than the Initial Level and (i) a Knock-In Event occurs, then: [(Final Level – Initial Level)/Initial Level]; or (ii) a Knock-In Event does not occur, then: zero.
|
|
Knock-In Level*:
|
Approximately 50% of the Initial Level.
|
|
Knock-In Event:
|
Occurs if the Final Level is equal to or less than the Knock-In Level.
|
|
Initial Level:
|
The closing level of the Underlying on the Trade Date.
|
|
Final Level:
|
The closing level of the Underlying on the Valuation Date.
|
|
Valuation Date:
|
February 24, 2020
|
|
Maturity Date:
|
March 2, 2020
|
|
CUSIP:
|
22547QH41
|
|
*To be determined on the Trade Date.
|
Benefits
|
•
|
|
If the Final Level is greater than the Initial Level, offers uncapped leveraged participation
in the appreciation of the Underlying.
|
|
•
|
|
Reduced downside risk due to a 50% contingent buffer.
|
Hypothetical Returns at Maturity
Percentage
Change
from
Initial Level to
Final Level
Underlying
|
Underlying
Return
(1)
|
Redemption
Amount
per $1,000
Principal Amount
(1)(2)
|
|
50%
|
77.50%
|
$1,775
|
|
40%
|
62.00%
|
$1,620
|
|
30%
|
46.50%
|
$1,465
|
|
20%
|
31.00%
|
$1,310
|
|
10%
|
15.50%
|
$1,155
|
|
0%
|
0.00%
|
$1,000
|
|
-10%
|
0%
|
$1,000
|
|
-20%
|
0%
|
$1,000
|
|
-40%
|
0%
|
$1,000
|
|
-50%
|
-50%
|
$500
|
|
-60%
|
-60%
|
$400
|
|
(1)
|
|
Assumes an Upside Participation Rate of 155%* (the midpoint of the expected range).
|
|
(2)
|
|
The hypothetical Redemption Amounts set forth above are for illustrative purposes
only and may not be the actual returns applicable to you. The numbers appearing in the table have been rounded for ease of analysis.
|
Certain
Product Risks
|
•
|
|
Your investment may result in a loss of up to 100% of the principal amount. The Redemption Amount will be less than the
principal amount if the Final Level is less than the Initial Level and a Knock-In Event occurs. In such case, you will be
fully exposed to any depreciation in the Underlying.
|
|
•
|
|
The value of the securities and the payment of any amount due on the securities are
subject to the credit risk of Credit Suisse.
|
|
•
|
|
The securities do not pay interest.
|
|
•
|
|
The return on the securities is affected by the Final Level and the occurrence of
a Knock-In Event.
|
(See “Additional Risk Considerations” on the next page.)
Product Profile
|
Horizon (years)
|
|
6 Year
|
|
Principal Repayment
|
|
Principal at Risk
|
|
Investment Objective
|
|
Appreciation
|
|
Market Outlook
|
|
Bullish
|
FINANCIAL PRODUCTS
FACT SHEET
|
|
Offering Period: February 4, 2014 – February 20, 2014
6 Year Accelerated Barrier Notes
Additional Risk Considerations
|
•
|
|
Prior to maturity, costs such as concessions and hedging may affect the value of the
securities.
|
|
•
|
|
Liquidity – The securities will not be listed on any securities exchange. Credit
Suisse (or its affiliates) intends to offer to purchase the securities in the secondary market but is not required to do so. Many
factors, most of which are beyond the control of the Issuer, will influence the value of the securities and the price at which
the securities may be purchased or sold in the secondary market. For example, the creditworthiness of the Issuer, including actual
or anticipated downgrades to the Issuer’s credit ratings, may be a contributing factor.
|
|
•
|
|
Potential Conflicts – We and our affiliates play a variety of roles in connection
with the issuance of the securities including acting as calculation agent, hedging our obligations under the securities and determining
the estimated value of the securities. The agent for this offering, Credit Suisse Securities (USA) LLC (“CSSU”), is
our affiliate. In accordance with FINRA Rule 5121, CSSU may not make sales in this offering to any discretionary account without
prior written approval of the customer.
|
|
•
|
|
The securities will be affected by a number of economic, financial, political, regulatory,
and judicial factors that may either offset or magnify each other.
|
|
•
|
|
As a holder of the securities, you will not have voting rights or rights to receive
cash dividends or other distributions with respect to the equity securities comprising the Underlying.
|
The risks set forth in the section entitled
“Product Risks” on the preceding page and this section “Additional Risk Considerations” are only intended
as summaries of some of the risks relating to an investment in the securities. Prior to investing in the securities, you should,
in particular, review the “Product Risks” and “Additional Risk Considerations” sections herein, the “Selected
Risk Considerations” section in the pricing supplement, and the “Risk Factors” section of the product supplement,
which set forth risks related to an investment in the securities.
Disclaimer
IRS Circular 230 Disclosure: Credit Suisse and
its affiliates do not provide tax advice. Accordingly, any discussion of U.S. tax matters contained herein (including any attachments)
is not intended or written to be used and cannot be used, in connection with the promotion, marketing or recommendation by anyone
unaffiliated with Credit Suisse of any of the matters address herein or for the purpose of avoiding U.S. tax-related penalties.
Investment suitability must be determined individually
for each investor, and the financial instruments described herein may not be suitable for all investors. The products described
herein should generally be held to maturity as early sales could result in lower than anticipated returns. This information is
not intended to provide and should not be relied upon as providing accounting, legal, regulatory or tax advice. Investors should
consult with their own advisors as to these matters.
This material is not a product of Credit Suisse
Research Departments. Financial Products may involve a high degree of risk, and may be appropriate investments only for sophisticated
investors who are capable of understanding and assuming the risks involved. Credit Suisse and its affiliates may have positions
(long or short), effect transactions or make markets in securities or financial instruments mentioned herein (or options with
respect thereto), or provide advice or loans to, or participate in the underwriting or restructuring of the obligations, issuers
of the stocks comprising the applicable index, indices or fund mentioned herein. Credit Suisse is a member of FINRA, NYSE and
SIPC. Clients should contact their salespersons at, and execute transactions through, a Credit Suisse entity qualified in their
home jurisdiction unless governing law permits otherwise.
You may revoke your offer to purchase the
securities at any time prior to the time at which we accept such offer on the date the securities are priced. We reserve the right
to change the terms of, or reject any offer to purchase the securities prior to their issuance. In the event of any changes to
the terms of the securities, we will notify you and you will be asked to accept such changes in connection with your purchase.
You may also choose to reject such changes in which case we may reject your offer to purchase.
This document is a summary of the terms of
the securities and factors that you should consider before deciding to invest in the securities. Credit Suisse has filed a registration
statement (including pricing supplement, product supplement, underlying supplement, prospectus supplement and prospectus) with
the Securities and Exchange Commission, or SEC, for the offering to which this offering summary relates. Before you invest, you
should read this summary together with the Preliminary Pricing Supplement dated February 4, 2014, Underlying Supplement dated
July 29, 2012, Product Supplement No. T-I dated March 23, 2012, Prospectus Supplement dated March 23, 2012 and Prospectus dated
March 23, 2012 to understand fully the terms of the securities and other considerations that are important in making a decision
about investing in the securities. You may get these documents without cost by visiting EDGAR on the SEC Web site at
www.sec.gov
.
Alternatively, Credit Suisse, any agent or any dealer participating in this offering will arrange to send you the pricing supplement,
product supplement, underlying supplement, prospectus supplement and prospectus if you so request by calling toll-free 1 (800)
221-1037.
You may access the pricing supplement related
to the offering summarized herein on the SEC website at:
http://www.sec.gov/Archives/edgar/data/1053092/000095010314000736/dp43661_424b2-t299.htm
You may access the product supplement, underlying
supplement, prospectus supplement and prospectus on the SEC website at
www.sec.gov
or
by clicking on the hyperlinks to each of the respective documents incorporated by reference in the pricing supplement.